Clinical Trial Update: Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and effectiveness of h5G1.1-mAb for dermatomyositis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• h5G1.1-mAb (h5G1.1-mAb)

Snippet

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Conditions: Dermatomyositis | Phase 2 | Status: COMPLETED